Promoting trained immunity with therapeutic nanobiologic compositions

Patent metadata

Field	Value
Publication number	US-2025268839-A1
Application number	US-202418927572-A
Country	US
Kind code	A1
Filing date	Oct 25, 2024
Priority date	Nov 21, 2017
Publication date	Aug 28, 2025
Grant date	—

Abstract

The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.

First claim

1 .- 32 . (canceled)

33 . A nanobiologic composition for promoting trained immunity, comprising:
a nanoscale assembly, wherein the nanoscale assembly is a multi-component carrier composition comprising: (a) a phospholipid, (b) a human apolipoprotein A-I (apoA-I) or a peptide mimetic of apoA-I, and (c) cholesterol and (d) a promoter drug that activates nucleotide-binding oligomerization domain 2 (NOD2) or Dectin-1, wherein the promoter drug that activates NOD2 is muramyl dipeptide (MDP), muramyl tripeptide (MTP), or a hydrophobic derivative of MDP or MTP; and wherein the promoter drug that activates Dectin-1 is a beta-glucan or a beta-glucan derivative, wherein the beta-glucan derivative is a 11-13 gluco-oligomer; and wherein said nanobiologic composition is a nanodisc or nanosphere with a size between about 8 nm and 400 nm in diameter.

34 . The nanobiologic composition of claim 33 , wherein the promoter drug is muramyl dipeptide (MDP), muramyl tripeptide (MTP), or a hydrophobic derivative thereof.

35 . The nanobiologic composition of claim 33 , wherein the promoter drug is a hydrophobic derivative of muramyl tripeptide (MTP).

36 . The nanobiologic composition of claim 35 , wherein the promoter drug is MTP derivatized with a phospholipid, aliphatic chain, or sterol.

37 . The nanobiologic composition of claim 33 , wherein the promoter drug is MDP derivatized with a phospholipid, aliphatic chain, or sterol.

38 . The nanobiologic composition of claim 33 , wherein the promoter drug is a muramyl tripeptide phosphatidylethanolamine.

39 . The nanobiologic composition of claim 33 , wherein the nanoscale assembly comprises a phospholipid and a lysophospholipid.

40 . The nanobiologic composition of claim 33 , wherein the nanoscale assembly phospholipid is 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), or mixtures thereof.

41 . The nanobiologic composition of claim 33 , wherein the nanoscale assembly phospholipid is DMPC.

42 . The nanobiologic composition of claim 39 , wherein the nanoscale assembly lysophospholipid is 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (MHPC), 1-palmitoyl-2-hexadecyl-sn-glycero-3-phosphocholine (PHPC), 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (SHPC), or mixtures thereof.

43 . The nanobiologic composition of claim 33 , wherein the nanobiologic composition is a nanosphere comprising a hydrophobic matrix core, and wherein the nanosphere is between about 30 nm and about 150 nm in diameter.

44 . The nanobiologic composition of claim 43 , wherein the hydrophobic matrix core comprises one or more triglycerides, fatty acid esters, hydrophobic polymers, sterol esters, or a combination thereof.

45 . The nanobiologic composition of claim 43 , wherein the hydrophobic matrix comprises one or more triglycerides.

46 . The nanobiologic composition of claim 45 , wherein at least one triglyceride is tricaprylin.

47 . The nanobiologic composition of claim 33 , wherein the nanobiologic composition is a nanodisc with a diameter between about 8 nm and about 35 nm in diameter.

48 . The nanobiologic composition of claim 33 , wherein the nanoscale assembly comprises: 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC); human apoA-I; and cholesterol; and wherein the promoter drug is a muramyl tripeptide phosphatidylethanolamine.

49 . A method of stimulating an anti-cancer immune response in a patient comprising administering the nanobiologic composition of claim 33 to the patient.

50 . The method of claim 49 further comprising administering a checkpoint inhibitor.

51 . The method of claim 49 , wherein the cancer is a cancer of the bladder, bone, brain, breast, cervix, chest, colon, endometrium, esophagus, eye, head, kidney, liver, lymph node, lung, mouth, neck, ovary, pancreas, prostate, rectum, skin, stomach, testis, throat, thyroid, or uterus.

52 . The method of claim 49 further comprising administering chemotherapy, radiation therapy, or both.

Assignees

• Icahn School Med Mount Sinai
• Stichting Katholieke Univ

Inventors

• Mulder Willem
• Ochando Jordi
• Fayad Zahi
• Netea Mihai
• Joosten Leo

Classifications

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K47/544

  Phospholipids · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• C07K14/775

  Apolipopeptides · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title